In the complex landscape of pharmaceutical manufacturing, intermediate compounds like Clidinium Bromide are indispensable. Identified by its CAS Number 3485-62-9, Clidinium Bromide is a critical pharmaceutical intermediate that forms the basis for numerous medications. This article highlights its chemical identity, physical attributes, and vital applications within the healthcare sector.

Physically, Clidinium Bromide is recognized as a white crystalline solid, a description consistent across various suppliers. Its molecular formula, C22H26BrNO3, and a molecular weight of 432.35 g/mol, are key identifiers for professionals involved in its procurement and utilization. The compound's primary value lies in its anticholinergic properties, which are fundamental to its therapeutic applications. These properties allow it to act as an antispasmodic, effectively reducing muscle spasms and secretions in the body.

The pharmaceutical industry utilizes Clidinium Bromide extensively as a raw material, particularly in the formulation of drugs designed to treat gastrointestinal ailments. Conditions such as Irritable Bowel Syndrome (IBS) and peptic ulcers often require treatments that can soothe the digestive tract and reduce discomfort. Clidinium Bromide plays a crucial role in these antispasmodic formulations by modulating the activity of the parasympathetic nervous system.

The production of Clidinium Bromide involves precise chemical synthesis to ensure a high level of purity, generally a minimum of 97%. This stringent requirement ensures that the intermediate is suitable for pharmaceutical use, where safety and efficacy are paramount. For pharmaceutical companies, the consistent supply of high-quality Clidinium Bromide for IBS treatment is essential for maintaining production pipelines and meeting market demand. The chemical synthesis and quality control processes are vital for its reliable integration into drug manufacturing.